Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories cGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%) (%)
Form 8-K Earnings Releases & Form 10-K MD&A ('sales of continuous glucose monitors')
Latest, FY2025
17.4%
Period ended Dec 31, 2025
Change on a year earlier
-4.4 pts
21.8% in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17.4% | -4.4 pts | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 21.8% | -3.7 pts | SEC Filing (0001628280-25-007110) ↗ |
| FY2023 | Dec 31, 2023 | 25.5% | +3.1 pts | SEC Filing (0001628280-24-005348) ↗ |
| FY2022 | Dec 31, 2022 | 22.4% | -14.4 pts | SEC Filing (0001628280-23-004026) ↗ |
| FY2021 | Dec 31, 2021 | 36.8% | -5.8 pts | SEC Filing (0001104659-22-025141) ↗ |
| FY2020 | Dec 31, 2020 | 42.6% | -27.2 pts | SEC Filing (0001104659-21-025751) ↗ |
| FY2019 | Dec 31, 2019 | 69.8% | – | SEC Filing (0001104659-20-023904) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories CGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%) (%), annual FY2019–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/cgm-yoy-org
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.